Jin Huimin, Xiang Yuying, Feng Yuqian, Zhang Yiting, Liu Shan, Ruan Shanming, Zhou Huamiao
The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China.
Center of Clinical Evaluation, Zhejiang Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang 310006, China.
Evid Based Complement Alternat Med. 2020 May 11;2020:3237451. doi: 10.1155/2020/3237451. eCollection 2020.
To evaluate the effectiveness and safety of acupuncture moxibustion therapy (AMT) for the breast cancer-related lymphedema (BCRL).
Four English databases (MEDLINE, PubMed, Embase, and Cochrane CENTRAL) and four Chinese databases were searched from their inception to Feb 1, 2020. Eligible randomized controlled trials (RCTs) investigating AMT against any type of controlled intervention in patients for BCRL and assessing clinically relevant outcomes (total effective rate, circumference difference, and Karnofsky performance score) were included. The methodological quality of all selected trials was estimated in accordance with the guidelines published by the Cochrane Collaboration. Review Manager 5.3 was used to conduct analyses.
Twelve eligible RCTs are confirmed. Most of the trials selected are regarded as low methodological quality. Compared with Western medicine, physiotherapy, and functional training, traditional AMT has significantly higher treatment effect (RR 1.03 (95% CI: 1.22, 1.45); < 0.00001). In comparison with physiotherapy, AMT is better in reducing edema symptoms (MD = -0.77; 95% CI (-1.13-0.41); < 0.00001). Moreover, pooled results demonstrate that AMT results in better outcomes than functional training and Western medicine in improving Karnofsky performance score of BCRL patients (SMD = 0.69; 95% CI (0.38-1.00); < 0.00001).
This systematic review and meta-analysis provides evidence that AMT is serviceable and safe in treating BCRL. With the limited number of available studies and methodology drawbacks, further high-quality RCTs with reasonable designs are still warranted.
评估艾灸疗法(AMT)治疗乳腺癌相关淋巴水肿(BCRL)的有效性和安全性。
检索了四个英文数据库(MEDLINE、PubMed、Embase和Cochrane CENTRAL)以及四个中文数据库,检索时间从各数据库建库至2020年2月1日。纳入符合条件的随机对照试验(RCT),这些试验研究了AMT与针对BCRL患者的任何类型对照干预措施,并评估了临床相关结局(总有效率、周长差异和卡诺夫斯基功能状态评分)。根据Cochrane协作网发布的指南评估所有入选试验的方法学质量。使用Review Manager 5.3进行分析。
确认了12项符合条件的RCT。所选试验大多被认为方法学质量较低。与西医、物理治疗和功能训练相比,传统AMT具有显著更高的治疗效果(RR 1.03(95%CI:1.22,1.45);<0.00001)。与物理治疗相比,AMT在减轻水肿症状方面效果更好(MD = -0.77;95%CI(-1.13 - 0.41);<0.00001)。此外,汇总结果表明,在改善BCRL患者的卡诺夫斯基功能状态评分方面,AMT比功能训练和西医产生更好的结局(SMD = 0.69;95%CI(0.38 - 1.00);<0.00001)。
本系统评价和荟萃分析提供了证据,表明AMT治疗BCRL有效且安全。鉴于现有研究数量有限且存在方法学缺陷,仍需要进一步开展设计合理的高质量RCT。